$ 0
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly undervalued vs peers
Data is available to registered users only
Data is available to registered users only
About
As of 2021, Baseline Productions, Inc. is actively pursuing opportunities for a merger or acquisition. Simultaneously, the company is working to bring its operations and status up-to-date. This strategic shift follows a significant development on October 9, 2017, when its Pharmaceutical Services Agreement (PSA) with Canteck Pharma, Inc. was terminated. The reason for this termination was the company's inability to secure the necessary licensing to proceed with its immunotherapeutic-based technology, which was specifically targeted at cancer indications, within Mexico.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'cheaper' than its peers.
Data is available to registered users only